BR9910626A - Polipeptìdeos hìbrido e de núcleo, e, processo para intensificar as propriedades farmacocinéticas de um polipeptìdeo de núcleo - Google Patents

Polipeptìdeos hìbrido e de núcleo, e, processo para intensificar as propriedades farmacocinéticas de um polipeptìdeo de núcleo

Info

Publication number
BR9910626A
BR9910626A BR9910626-4A BR9910626A BR9910626A BR 9910626 A BR9910626 A BR 9910626A BR 9910626 A BR9910626 A BR 9910626A BR 9910626 A BR9910626 A BR 9910626A
Authority
BR
Brazil
Prior art keywords
core
pharmacokinetic properties
polypeptides
hybrid
core polypeptide
Prior art date
Application number
BR9910626-4A
Other languages
English (en)
Inventor
Shawn Barney
Kelly I Guthrie
Gene Merutka
Mohmed K Anwer
Dennis M Lambert
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of BR9910626A publication Critical patent/BR9910626A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"POLIPEPTìDEOS HìBRIDO E DE NúCLEO, E, PROCESSO PARA INTENSIFICAR AS PROPRIEDADES FARMACOCINéTICAS DE UM POLIPEPTìDEO DE NúCLEO". A presente invenção refere-se a seq³ências de peptídeos intensificadores derivadas originalmente de várias seq³ências de proteína de invólucro retroviral (gp41) que intensificam as propriedades farmacocinéticas de qualquer polipeptídeo de núcleo ao qual estão ligadas. A invenção baseia-se na verificação de que polipeptídeos híbridos compreendendo as seq³ências de peptídeos intensificadores ligados ao polipeptídeo de núcleo possuem propriedades farmacocinéticas intensificadas, como uma maior meia-vida. A invenção refere-se adicionalmente a processos para intensificar as propriedades farmacocinéticas de qualquer polipeptídeo de núcleo através de ligação das seq³ências de peptídeos intensificadores ao polipeptídeo de núcleo. Os polipeptídeos de núcleo a serem utilizados na prática da invenção podem incluir qualquer peptídeo farmacologicamente útil, por exemplo, como um reagente terapêutico ou profilático.
BR9910626-4A 1998-05-20 1999-05-20 Polipeptìdeos hìbrido e de núcleo, e, processo para intensificar as propriedades farmacocinéticas de um polipeptìdeo de núcleo BR9910626A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/082,279 US6258782B1 (en) 1998-05-20 1998-05-20 Hybrid polypeptides with enhanced pharmacokinetic properties
PCT/US1999/011219 WO1999059615A1 (en) 1998-05-20 1999-05-20 Hybrid polypeptides with enhanced pharmacokinetic properties

Publications (1)

Publication Number Publication Date
BR9910626A true BR9910626A (pt) 2006-01-03

Family

ID=22170199

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910626-4A BR9910626A (pt) 1998-05-20 1999-05-20 Polipeptìdeos hìbrido e de núcleo, e, processo para intensificar as propriedades farmacocinéticas de um polipeptìdeo de núcleo

Country Status (22)

Country Link
US (3) US6258782B1 (pt)
EP (1) EP1079846A4 (pt)
JP (1) JP2002515449A (pt)
KR (1) KR100742789B1 (pt)
CN (1) CN1205995C (pt)
AU (1) AU766995C (pt)
BR (1) BR9910626A (pt)
CA (1) CA2332338A1 (pt)
HK (1) HK1039747A1 (pt)
HR (1) HRP20000789A2 (pt)
HU (1) HUP0101826A3 (pt)
ID (1) ID29141A (pt)
IL (2) IL139702A0 (pt)
MX (1) MXPA00011314A (pt)
NO (1) NO20005836L (pt)
NZ (1) NZ508352A (pt)
PL (1) PL344342A1 (pt)
RU (1) RU2236865C2 (pt)
TR (1) TR200100163T2 (pt)
WO (1) WO1999059615A1 (pt)
YU (1) YU71800A (pt)
ZA (1) ZA200006642B (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224003C (en) * 1995-06-07 2010-04-13 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
EP1264840B1 (en) * 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6277974B1 (en) 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US6623741B1 (en) * 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
US6528308B1 (en) 2000-03-16 2003-03-04 Duke University Suppressor of HIV replication and transcription
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
KR100447943B1 (ko) * 2000-11-06 2004-09-08 한국과학기술연구원 Ｈｉｖ의 감염 억제 펩타이드
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
EP1479691B1 (en) * 2001-05-31 2006-11-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors for HIV infection
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EP1752469B1 (en) * 2001-05-31 2008-10-29 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors for HIV infection
NZ530481A (en) * 2001-06-07 2007-11-30 Skinmedica Inc Compositions comprising cell culture medium conditioned by cells grown in three-dimensional culture
ES2525317T3 (es) 2001-06-15 2014-12-22 F. Hoffmann-La Roche Ag Producción recombinante de inhibidores de la fusión antivirales peptídicos
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20040023334A1 (en) * 2001-08-30 2004-02-05 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
FR2832715A1 (fr) * 2001-11-29 2003-05-30 Hippocampe Polypeptides inhibiteurs de l'infectivite des virus de l'immunodeficience humaine
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
EP1471928A1 (en) * 2002-02-07 2004-11-03 Delta Biotechnology Limited Hiv inhibiting proteins
RU2322454C2 (ru) 2002-02-22 2008-04-20 Проджиникс Фармасьютикалз, Инк. Антитело против ccr5
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2003225710A1 (en) * 2002-03-06 2003-09-22 Arizona Board Of Regents Composition and method for enhancing immune response
EP1546193A1 (en) * 2002-07-24 2005-06-29 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide
AU2003262886A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
EA007918B1 (ru) * 2002-09-24 2007-02-27 Франтиэ Биотекнолоджиз Ко., Лтд. Пептидные производные-ингибиторы слияния при вич-инфекции
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
ATE514718T1 (de) * 2003-04-04 2011-07-15 Univ Lausanne Peptabody für krebsbehandlung
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP1466924B9 (en) * 2003-04-11 2013-06-19 Institut Pasteur Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
US7379700B2 (en) * 2003-05-06 2008-05-27 Canon Kabushiki Kaisha Image reading apparatus with rotatable internal and external guides
WO2004106364A1 (en) * 2003-08-05 2004-12-09 Cornell Research Foundation, Inc. Stabilizing peptides and their use in the preparation of stabilized hiv inhibitors
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
US7744897B2 (en) 2003-12-23 2010-06-29 Dillon Susan B Human immunodeficiency virus gp41 mimetibody polypeptides
WO2005067960A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
EP1732612B1 (en) * 2004-04-08 2009-09-16 Jado Technologies GmbH Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
US20070041943A1 (en) * 2004-12-29 2007-02-22 Children's Hospital Research Expression of virus entry inhibitors and recombinant AAV thereof
MX2008000984A (es) * 2005-07-22 2008-04-04 Progenics Pharm Inc Metodos para reducir la carga viral en pacientes infectados con vih-1.
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
AR059300A1 (es) 2006-02-02 2008-03-26 Trimeris Inc Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
JP5102833B2 (ja) * 2006-07-24 2012-12-19 バイオレクシス ファーマシューティカル コーポレーション エキセンディン融合タンパク質
BRPI0715794A2 (pt) 2006-08-17 2013-07-23 Hoffmann La Roche conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007331195A1 (en) 2006-12-12 2008-06-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2139526A4 (en) * 2007-04-03 2010-07-14 Trimeris Inc NEW FORMULATIONS TO RELEASE ANTIVIRAL PEPTIDE THERAPEUTICS
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
ES2543166T3 (es) * 2009-03-31 2015-08-17 University Of Washington Composiciones y métodos para modular la actividad de proteínas reguladoras del complemento sobre células diana
EP2413975A1 (en) * 2009-04-01 2012-02-08 Yeda Research and Development Co. Ltd. Lipopeptide inhibitors of hiv-1
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
KR20130045385A (ko) 2010-09-14 2013-05-03 에프. 호프만-라 로슈 아게 세르핀-핑거 융합 폴리펩티드
WO2013096939A1 (en) * 2011-12-23 2013-06-27 Sri International Selective binding compounds
CN104136455B (zh) * 2012-02-27 2017-05-17 中国人民解放军军事医学科学院毒物药物研究所 抗hiv‑1多肽及其用途
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
JP6306593B2 (ja) * 2012-09-13 2018-04-04 ユニベルシテ ドゥ ジュネーブ 細胞透過性ペプチド
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN105646717B (zh) * 2016-01-26 2020-06-09 复旦大学 一种长效hiv融合抑制剂及其应用
EP3214093A1 (en) * 2016-03-03 2017-09-06 Fondation The Ark Fusion respiratory syncytial virus inhibitors and use thereof
CN106279373B (zh) * 2016-08-17 2020-01-24 广州宏柯源生物科技有限公司 一种多肽起泡剂、其制备方法及应用
MX2019002968A (es) 2016-09-21 2019-10-15 Amal Therapeutics Sa Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal.
EP3676286A1 (de) * 2017-08-29 2020-07-08 Pharis Biotec GmbH Protransduzin-d - verbesserter enhancer des gentransfers
CN110357968B (zh) * 2018-04-08 2023-08-25 吉林省汇融生物科技有限公司 抗肿瘤融合蛋白及其制法和应用
CN116162136A (zh) * 2021-11-24 2023-05-26 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
AU626797B2 (en) * 1987-09-08 1992-08-13 Albany Medical College Immunogenic composites capable of selectively inducing antibody production, pharmaceutical compositions employing the same and method of selectively inducing antibody production
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
DE69326069T2 (de) 1992-07-20 2000-03-23 Univ Durham Zusammensetzungen die die hiv replikation inhibieren
US5358934A (en) * 1992-12-11 1994-10-25 The United States Of America As Represented By The Secretary Of Agriculture Materials and methods for control of pests
US5464934A (en) 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties

Also Published As

Publication number Publication date
WO1999059615A9 (en) 2000-06-22
WO1999059615A1 (en) 1999-11-25
AU766995C (en) 2004-12-02
US6258782B1 (en) 2001-07-10
JP2002515449A (ja) 2002-05-28
IL139702A (en) 2007-10-31
US6348568B1 (en) 2002-02-19
ZA200006642B (en) 2001-05-28
IL139702A0 (en) 2002-02-10
MXPA00011314A (es) 2003-04-22
NO20005836L (no) 2001-01-19
KR100742789B1 (ko) 2007-07-25
TR200100163T2 (tr) 2001-06-21
HK1039747A1 (zh) 2002-06-21
HUP0101826A2 (hu) 2001-09-28
ID29141A (id) 2001-08-02
NO20005836D0 (no) 2000-11-17
EP1079846A1 (en) 2001-03-07
YU71800A (sh) 2004-05-12
CN1310626A (zh) 2001-08-29
AU4194999A (en) 1999-12-06
HUP0101826A3 (en) 2005-12-28
PL344342A1 (en) 2001-11-05
NZ508352A (en) 2004-02-27
EP1079846A4 (en) 2003-01-02
AU766995B2 (en) 2003-10-30
KR20010043681A (ko) 2001-05-25
CN1205995C (zh) 2005-06-15
CA2332338A1 (en) 1999-11-25
RU2236865C2 (ru) 2004-09-27
US6562787B1 (en) 2003-05-13
HRP20000789A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
BR9910626A (pt) Polipeptìdeos hìbrido e de núcleo, e, processo para intensificar as propriedades farmacocinéticas de um polipeptìdeo de núcleo
BR0012287A (pt) Polipeptìdeo hìbrido, polipeptìdeo núcleo, e, processo para intensificar, as propriedades farmacocinéticas de um polipeptìdeo núcleo
Pizzo et al. The effect of plasmin on the subunit structure of human fibrinogen
Creighton The single-disulphide intermediates in the refolding of reduced pancreatic trypsin inhibitor
Kroemker et al. Intramolecular interactions in vinculin control α-actinin binding to the vinculin head
Nyitray et al. The proteolytic substructure of light meromyosin. Localization of a region responsible for the low ionic strength insolubility of myosin.
Fullmer et al. Bovine intestinal calcium-binding proteins: Purification and some properties
Yaneva et al. Purification of an 86-70 kDa nuclear DNA-associated protein complex
BR9507618A (pt) Frações polipeptidicas solúveis da proteína lag-3 processo de produção composição terapêutica anticorpos anti-idiotipo
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
Riseman et al. The calmodulin and F-actin binding sites of smooth muscle caldesmon lie in the carboxyl-terminal domain whereas the molecular weight heterogeneity lies in the middle of the molecule
DE69132902D1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
Calvete et al. Characterisation of the conformational and quaternary structure‐dependent heparin‐binding region of bovine seminal plasma protein PDC‐109
WO1994017097B1 (en) Synthetic fibronectin fragments as inhibitors of retroviral infections
KOMIYA et al. Bovine plasma kininogens: III. Structural comparison of high molecular weight and low molecular weight kininogens
DE60114018D1 (de) Von zellen präsentierte peptide
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
KR850006550A (ko) 단백질의 제조방법
Kageyama et al. The complete amino acid sequence of monkey pepsinogen A.
JPH05240855A (ja) タンパク質の同定または測定方法、およびそれの適用
KR960705038A (ko) 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
ATE327251T1 (de) Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen
DE69736158D1 (de) Glutamine: Fructose-6-Phosphat Amidotransferase (GFAT), ihre Herstellung und Verwendung
BR9910725A (pt) Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14
Imamura et al. A novel nonmuscle alpha-actinin. Purification and characterization of chicken lung alpha-actinin.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 10 (VIII E IX) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.